Introduction
Chronic heart failure is the most common cause of hospital admissions in Western countries, and its prevalence is expected to increase further. The current medical treatments target in particular the excessive activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system. Beyond these neuroendocrine interventions, few novel targets to treat heart failure have been identified. Over recent years, metabolic aspects to heart failure have gained increasing interest, since in patients with heart failure, the energy stores of the heart are depleted, with decreased ratios of phosphocreatine to adenosine triphosphate (ATP) predicting an adverse outcome (Neubauer, 2007) . More recent work suggests that while depletion of phosphocreatine per se may limit maximal exercise capacity, maladaptive remodelling -typically closely associated with the prognosis -is not affected by such an energetic deficit (Lygate et al. 2013) . Instead, the accumulation of metabolic intermediates of glycolysis and fatty acid oxidation as well as oxidative stress, which can all induce maladaptive signalling in their own right, may be the more relevant triggers for disease progression than the mere depletion of ATP (or phosphocreatine) stores (Chatham & Young, 2012; Nickel et al. 2013) .
In the plasma and hearts of patients with heart failure, the levels of oxidative stress are increased and correlate with left ventricular dysfunction (Belch et al. 1991; Maack et al. 2003) . Oxidative stress is an imbalance between the production and detoxification of reactive oxygen species (ROS), and their major sources in the heart are NADPH oxidases, uncoupled nitric oxide synthases and mitochondria (Burgoyne et al. 2012; Nickel et al. 2014) .
Mitochondria are considered to be the main source of ROS in most cell types and in particular in cardiac myocytes by most (Turrens, 2003; Adam-Vizi, 2005; Balaban et al. 2005; Hool et al. 2005; Murphy, 2009) but not all authors (Brown & Borutaite, 2012) . Oxidative stress impairs excitation-contraction (EC) coupling in cardiac myocytes, causes arrhythmias (Wagner et al. 2013; Yang et al. 2015) , activates pro-hypertrophic signalling (Ago et al. 2008; Erickson et al. 2008) and induces apoptotic and/or necrotic cell death through activation of the permeability transition pore (Halestrap, 2005) . In particular, mitochondrial ROS play a causal role in the development and progression of heart failure in response to various pathological stimuli, such as ischaemia-reperfusion, pressure overload and angiotensin II (Matsushima et al. 2006; Dai et al. 2011 Dai et al. , 2012 . Moreover, mitochondria appear to amplify ROS production from other ROS sources, such as NADPH oxidase, by a mechanism termed ROS-induced ROS release (Zorov et al. 2000; Aon et al. 2003; Brandes, 2005; Kimura et al. 2005; Dai et al. 2011; Maack & Böhm, 2011) . Therefore, understanding the regulation of mitochondrial ROS is key to eventually developing treatments that may prevent or ameliorate heart failure development beyond the inhibition of neuroendocrine activation.
In the past 10 years, we (Nickel et al. 2014 (Nickel et al. , 2015 and others (Aon et al. 2010; Gauthier et al. 2013; Kembro et al. 2013 ) have developed a concept in which ROS emission from cardiac mitochondria is dynamically regulated by Ca 2+ and ADP, with the redox state of mitochondrial pyridine nucleotides as a central level of control. According to this concept, a mismatch between decreased mitochondrial Ca 2+ uptake and increased cardiac workload induces net oxidation of NADH, which also oxidizes NADPH and thereby depletes the anti-oxidative capacity of the matrix, giving rise to excessive emission of H 2 O 2 (Fig. 1) . In the following, we will discuss the pathophysiological basis of this concept and address current controversies, future directions of research and potential points of intervention. (Bers, 2006) . A physiological increase in workload is triggered by β-adrenergic stimulation, elevating the rate and amplitude of cytosolic Ca 2+ transients and thereby increasing force generation at the myofilaments. Through this increase of work, ATP is hydrolysed to adenosine diphosphate (ADP), and after shuttling into mitochondria via the adenine nucleotide transporter, ADP activates the F 1 F o -ATPase to regenerate ATP (Fig. 1A) . This hastens electron flux along the electron transport chain (ETC), oxidizing NADH to NAD + (so-called 'pull' condition; Fig. 1A ). At the same time, Ca 2+ is taken up into mitochondria via the mitochondrial Ca 2+ uniporter (MCU), where it activates Krebs cycle dehydrogenases to adapt NADH regeneration to ETC-induced oxidation ('push' condition). This dual role of Ca 2+ , i.e. increasing both energy consumption ('pull' on electrons along the ETC) and regeneration ('push' of electrons from the Krebs cycle into the ETC), is termed 'parallel activation' (Fig. 1A) (Balaban, 2002; Cortassa et al. 2006) .
The discovery of the molecular identity of the MCU (Baughman et al. 2011; De Stefani et al. 2011 ) has led to the consecutive identification of its various regulatory proteins, such as MICU1, MICU2, MCUR and EMRE, together forming the mitochondrial Ca 2+ 'uniplex' Kamer & Mootha, 2015) (Kwong (2017) , in this issue). Since the affinity of the MCU for Ca 2+ is rather low (i.e. in the micromolar range), the close association of mitochondria to the SR creates a Ca 2+ microdomain between these two organelles that allows efficient mitochondrial Ca 2+ uptake and privileges this pathway over trans-sarcolemmal Ca 2+ influx . This microdomain is governed by physical tethers that link both organelles, one of these being mitofusin 2 (Mfn-2) (de Brito & Scorrano, 2008; Chen et al. 2012; Naon et al. 2016) (Fig. 1A) . Ca 2+ is exported from mitochondria by a Na + /Ca 2+ (Li + ) exchanger (Palty et al. 2010) , whose kinetics are much slower than those of uptake via the MCU and therefore Ca 2+ accumulates in mitochondria when amplitude and/or rate of cytosolic Ca 2+ transients increase (Di Lisa et al. 1993; Maack et al. 2006) .
The absolute amounts of Ca 2+ taken up by mitochondrial, and whether these are consequential for cytosolic Ca 2+ handling, is currently not fully resolved yet. While in other, non-cardiomyocyte cell types, mitochondrial Ca 2+ uptake commonly buffers cytosolic Ca 2+ (Rizzuto & Pozzan, 2006) , this has been suggested to be the case in cardiac myocytes as well in some models, but refuted by others, as previously reviewed (O'Rourke & Blatter, 2009; Kohlhaas & Maack, 2013; Williams et al. 2013) . These controversies are related to technical challenges, but also potential species differences. In this context, it should be considered that in humans, cardiac output during exertion can increase 4-to 6-fold (Chapman et al. 1960; Grimby et al. 1966) , while in the mouse, baseline heart rate is already ß600 beats per minute and increases by a factor of only ß1.5 during maximal exertion with no increase in blood pressure (Desai et al. 1997; Georgakopoulos & Kass, 2001) , indicating that workload variance requiring energetic adaptations is clearly much smaller in mice than in humans. Since mitochondrial Ca 2+ uptake is required to match energy supply to demand, particularly during β-adrenergic stimulation, it is likely that in humans, mitochondrial Ca 2+ uptake may play a more important role than in the mouse. In fact, when comparing MCU current density in various organs within the mouse, it is lowest in the heart (Fieni et al. 2012 ). However, no study has systematically compared cardiac MCU current densities between different species so far. Therefore, the interesting results obtained in mice with genetic inactivation of the MCU (Pan et al. 2013; Kwong et al. 2015; Luongo et al. 2015; Rasmussen et al. 2015; Wu et al. 2015) , which will be discussed in more detail further below, have to be extrapolated with some care and may to some extent underestimate the importance of mitochondrial Ca 2+ uptake in the human situation.
Regulation of mitochondrial ROS emission
During respiration, the superoxide anion radical ( . O 2 − ) is generated at complexes I and III of the ETC, and is dismutated to hydrogen peroxide (H 2 O 2 ) by the Mn 2+ -dependent superoxide dismutase (Balaban et al. 2005; Murphy, 2009; Chen & Zweier, 2014; Zorov et al. 2014; Murphy et al. 2016) . H 2 O 2 is then detoxified by glutathione peroxidase (GPX) and the thioredoxin/peroxiredoxin systems that all require reduced NADPH (Fig. 1A) . The regeneration of NADPH is governed by enzymes that derive their substrates from the Krebs cycle, in particular, isocitrate dehydrogenase and nicotinamide nucleotide transhydrogenase (NNT) (Ying, 2008; Nickel et al. 2015) (Fig. 1A) . Therefore, Ca 2+ -induced stimulation of the Krebs cycle not only matches energy supply to demand, but also regenerates the antioxidative capacity of the matrix to prevent the emission of H 2 O 2 during transitions of workload . Together with studies from isolated mitochondria, this helped to establish the concept of a 'redox-optimized ROS balance' (Aon et al. 2010) , in which the physiological steady state in cardiac mitochondria is tuned to an intermediate redox state that on the one hand prevents excessive formation of ROS at the ETC under highly reduced conditions (Starkov & Fiskum, 2003; Balaban et al. 2005) , and on the other prevents depletion of the antioxidative capacity under highly oxidized conditions (Aon et al. 2010; Gauthier et al. 2013; Kembro et al. 2013) .
Pathological alterations in heart failure
In systolic heart failure, contractile dysfunction is the result of decreased systolic Ca 2+ transients, and this is primarily related to decreased SR Ca 2+ load secondary to lowered SR Ca 2+ -ATPase activity and leaky ryanodine receptors (Bers, 2006) (Fig. 1A) . On the other hand, the cytosolic Na + concentration is elevated, which activates the reverse-mode of the sarcolemmal Na + /Ca 2+ exchanger to contribute to cytosolic Ca 2+ influx during the action potential (Armoundas et al. 2003; Weber et al. 2003) (Fig. 1A) . While this partly compensates for decreased SR Ca 2+ release (Weisser-Thomas et al. 2003) , the rather slow trans-sarcolemmal Na + /Ca 2+ exchanger-mediated Ca 2+ influx (Sipido et al. 1997 ) is less efficient for mitochondrial Ca 2+ uptake . Furthermore, elevated cytosolic Na + accelerates mitochondrial Ca 2+ efflux via the mitochondrial Na + /Ca 2+ (Li + ) exchanger (Maack et al. 2006; Liu & O'Rourke, 2008; (Fig. 1A) . Finally, in human cardiac mitochondria from patients with heart failure, the open probability of the MCU is decreased (Michels et al. 2009 ). Therefore, deterioration of EC coupling in heart failure compromises the well-tuned mitochondrial Ca 2+ uptake machinery. This has consequences for both energy supply-and-demand matching as well as the anti-oxidative capacity: in isolated cardiac myocytes from a guinea-pig model of systolic heart failure, NADH and NADPH oxidized, decreasing the amount of reducing equivalents for ATP production at the ETC and provoking the emission of ROS (Fig. 1A) (Liu & O'Rourke, 2008; . Since the inhibition of the mitochondrial Na + /Ca 2+ (Li + ) exchanger prevented NAD(P)H oxidation in myocytes (Liu & O'Rourke, 2008) and the development of heart failure in vivo (Liu et al. 2014) , the Na + -induced redox and energetic mismatch may play a causal role for heart failure progression and possibly represent a potential novel therapeutic target for patients with heart failure. However, this approach has not been followed up by large animal or clinical studies yet.
Mitochondrial transhydrogenase: the yin and yang of antioxidative capacity
Besides contractile dysfunction of the heart, cardiac haemodynamics are further compromised by an elevation of cardiac afterload due to increased systemic vascular resistance (Mason et al. 1964 ) as a result of the neuroendocrine activation that triggers vasoconstriction (Francis et al. 1984) . We recently identified a mechanism in which the mere increase in cardiac afterload provokes mitochondrial ROS emission (Nickel et al. 2015) . The NADH and NADPH pools are directly linked by NNT, catalysing the reaction NADH + NADP + ↔ NADPH + NAD + , which is coupled to the protonmotive force ( μ H ; Fig. 1A) . In energized mitochondria, the forward NNT reaction towards NADPH regeneration is strongly favoured and therefore NNT is considered a key anti-oxidative enzyme (Rydstrom, 2006) . Intriguingly, the most commonly used mouse strain, C57BL/6J, but not C57BL/6N, has a loss-of-function mutation in the gene encoding NNT (Nnt), which causes oxidative stress and impairs ATP production in pancreatic islet cells, leading to glucose intolerance in this strain (Toye et al. 2005; Freeman et al. 2006) . Furthermore, the Nnt mutation sensitized BL/6J hearts to develop cardiomyopathy upon deletion of Mn 2+ -dependent superoxide dismutase (Huang et al. 2006; Kim et al. 2010) . In contrast to this anti-oxidative role, we observed that in response to an increase in cardiac afterload, NNT can reverse its direction when oxidation of NADH at the ETC outweighs its Krebs cycle-mediated regeneration, consuming NADPH towards NADH and ATP regeneration, but at the cost of the anti-oxidative capacity (Nickel et al. 2015) (Fig. 1B) . The ensuing oxidative stress accounts for necrosis, left ventricular dysfunction and death during pressure overload, which was prevented in BL/6J mice (with inactivated NNT) or when BL/6N mice (with intact NNT) were treated with SS-31 (Nickel et al. 2015) , a tetrapeptide that accumulates ß1000-fold in mitochondria and ameliorates mitochondrial ROS production (Szeto, 2014) . While initial experiments suggested that SS-31 was a ROS scavenger (Zhao et al. 2004) , more recent work suggests J Physiol 595.12 that it does not have direct anti-oxidative effects (Brown et al. 2014) , but binds to cardiolipin, an essential phospholipid of the inner mitochondrial membrane (Szeto, 2014) . This interaction with SS-31 protects cardiolipin from oxidation and dysfunction, preventing disassembly of the ETC supercomplexes and thereby energetic deficit and mitochondrial ROS production (Szeto, 2014) . SS-31 also improved left ventricular function in the short and long term in a dog model of heart failure (Sabbah et al. 2016 ) and is currently being tested in phase II clinical trials on patients with systolic (NCT02788747, NCT02914665) and diastolic heart failure (NCT02814097).
Although the reverse-mode of NNT mediates oxidative stress during pathological cardiac workload, targeting NNT itself may not be a valuable pharmacological concept since the forward mode of NNT is required in most cells and conditions for anti-oxidative capacity (Rydstrom, 2006) , and C57BL/6J mice, which lack a functional NNT, have impaired glucose tolerance and thereby are more prone to develop diabetes. Furthermore, mutations of Nnt in humans are associated with familial glucocorticoid deficiency (Meimaridou et al. 2012) . Therefore, inhibiting NNT in humans globally may cause more harm than benefit.
An alternative therapeutic approach to reduce mitochondrial ROS is targeting the antioxidant electron acceptor ubiquinone to mitochondria using lipophilic cations, as with mitoquinone (MitoQ) (Murphy, 2016) . MitoQ reduced infarct size after cardiac ischaemiareperfusion (Adlam et al. 2005) and ameliorated cardiac remodelling in hypertensive rats (Graham et al. 2009 ). In clinical trials, MitoQ ameliorated hepatic necroinflammation in patients with hepatitis C (Gane et al. 2010) , but had neutral results in patients with Parkinson's disease (Snow et al. 2010 ). MitoQ has not yet been tested in patients with cardiovascular diseases.
Lessons learned from novel MCU-deficient mouse models for bioenergetic feedback coupling
After the molecular identity of the MCU was resolved, three different mouse models with either constitutive global (Pan et al. 2013; Holmström et al. 2015) or conditional cardiac myocyte-specific MCU knock-out (KO) (Kwong et al. 2015; Luongo et al. 2015) or overexpression of a dominant negative (DN-) MCU Wu et al. 2015) were generated (reviewed by Kwong (2017) in this issue). They all have in common that although mitochondria isolated from hearts are unable to rapidly accumulate Ca 2+ , their cardiac and/or cardiomyocyte function is normal in the absence of β-adrenergic receptor (β-AR) stimulation, indicating that MCU-mediated mitochondrial Ca 2+ uptake is required during physiological increases of workload, but not to sustain cardiac function at rest. Interestingly, mice with cardiomyocyte-specific MCU-KO had limited capacity to sprint at high speed (Kwong et al. 2015) , which was attributed to a delay and/or blunting of the positive inotropic, but not chronotropic, effect of catecholamines in vivo (Kwong et al. 2015; Luongo et al. 2015) . In DN-MCU mice, both the positive inotropic and the chronotropic responses to β-AR stimulation were blunted Wu et al. 2015) . In both models, cytosolic Ca 2+ concentrations in isolated cardiac myocytes were unaffected at baseline, but increased during systole in response to β-AR stimulation in the absence of an MCU (Luongo et al. 2015; Rasmussen et al. 2015) , in agreement with a study on neonatal cardiac myocytes with siRNA-induced silencing of the MCU. This may suggest that, at least to some extent, mitochondrial Ca 2+ uptake may contribute to cytosolic Ca 2+ buffering, which, however, is a subject of continual debate (O'Rourke & Blatter, 2009; Williams et al. 2013) . Rasmussen et al. (2015) argue that this increase in cytosolic Ca 2+ may increase ATP demand through the activation of EC coupling.
As a metabolic consequence, and in agreement with our previous results on guinea pig cardiac myocytes, in which we acutely inhibited the MCU with Ru360 , the β-AR-induced stimulation of Krebs cycle-mediated NAD(P)H production is blunted also by genetic MCU inactivation (Luongo et al. 2015; Wu et al. 2015) . In quiescent cells, in which little ATP is consumed and thereby only a small ADP-induced 'pull' on electrons along the ETC occurs, β-AR stimulation increases NAD(P)H, while MCU inactivation blunts this increase (Fig. 2B) (Luongo et al. 2015; Wu et al. 2015) . In contrast, in working hearts of wild-type animals, the redox states of NADH/NAD + and NADPH/NADP + remained balanced after β-AR stimulation (Luongo et al. 2015) , in agreement with the concept of the 'parallel activation' of 'push' and 'pull' conditions ( Fig. 2A) . In MCU-KO hearts, NADH/NAD + and NADPH/NADP + oxidized after β-AR stimulation (Luongo et al. 2015) , indicating that 'pull' (through ATP consumption) now outweighs the 'push' (in the absence of Ca 2+ -induced and Krebs cycle-mediated NADH production; Figs 1A and 2B ). These data are in agreement with our previous results on beating guinea pig cardiac myocytes .
In experiments on the MCU-KO model, Ca 2+ activated respiration and ATP production in wild-type mitochondria that respired maximally in the presence of ADP ('state 3' respiration) (Kwong et al. 2015; Luongo et al. 2015) . However, computational modelling predicted that during state 3 respiration, when respiratory control is dominated by the ADP-induced acceleration of electron flux along the ETC ('pull'), Ca 2+ -induced activation of the Krebs cycle with increased NADH generation would only increase ATP production by 5% . In addition to this Ca 2+ -mediated 'push' effect on NADH, however, Ca 2+ can also directly activate the F 1 F o -ATPase by ß2-fold (Territo et al. 2000) . Therefore, the observed Ca 2+ -induced (and MCU-sensitive) acceleration of O 2 consumption rates (Kwong et al. 2015; Luongo et al. 2015) are therefore presumably related to both Ca 2+ -induced activation the Krebs cycle and of the F 1 F o -ATPase (arrow in Fig. 2A) .
One conflicting observation from studies on genetically modified mice deserves further considerations. While in both the conditional MCU-KO and the DN-MCU model, MCU inactivation increased cytosolic Ca 2+ transients in unloaded cardiac myocytes, it decreased (and/or delayed) the inotropic response to β-AR stimulation or an increase in stimulation rate in whole hearts (Kwong et al. 2015; Luongo et al. 2015; Rasmussen et al. 2015) . It is unlikely that a decrease of myofilament Ca 2+ affinity accounts for this effect, since under baseline conditions, contractility Figure 2 . The impact of deficient mitochondrial Ca 2+ uptake on mitochondrial redox state and energetics A, control of respiration from upstream by Ca 2+ , which increases the availability of NADH through the Krebs cycle (KC) to 'push' electrons into the electron transport chain (ETC), and from downstream by ADP, which 'pulls' electrons (e − ) down the ETC to regenerate the proton gradient ( H + ) that fuels the F 1 F o -ATPase. B, changes that occur in the control of respiration and redox state, according to experimental results by Luongo et al. 2015 , Kwong et al. 2015 . Abbreviations: ATPases, energy consumption by myosin ATPase, SR Ca 2+ -ATPase, Na + /K + -ATPase and other ATP-consuming enzymes; ECC, excitation-contraction coupling; NNT, nicotinamide nucleotide transhydrogenase; PCr, phosphocreatinine. Red arrows indicate increases or decreases.
was similar in wild-type and MCU-deficient mouse hearts. It may therefore be assumed that the more cardiac workload increases, NADH oxidation may actually limit electron supply of the ETC and thereby ATP production. This would further demand that decreases in ATP affect contraction and relaxation. In fact, the SR Ca 2+ -ATPase is the enzyme that is most sensitive to a decrease in the free energy of ATP (Tian & Ingwall, 1996) . Furthermore, the parallel oxidation of NADPH/NADP + may provoke excessive emission of H 2 O 2 from mitochondria Nickel et al. 2015) , which may additionally hamper EC coupling (Wagner et al. 2013; Yang et al. 2015) . This, however, remains to be addressed by future studies.
Conclusions
There is now ample evidence for the tight and bidirectional interplay between cytosolic ion handling, mitochondrial redox regulation and ATP production in cardiac myocytes. Mitochondrial Ca 2+ uptake and its impact on the redox state of pyridine nucleotides is a central element of this interplay (Fig. 1A) , and disease conditions that interfere at this level are likely to induce catastrophic events that induce contractile dysfunction, arrhythmias and maladaptive remodelling through oxidative stress and energetic deficit. The data of the novel mouse models have aided in further characterization of this interplay, but since the dynamic range of cardiac workloads is much smaller in the mouse than in humans, and mitochondrial Ca 2+ uptake is required for matching ATP supply to demand particularly during these variations, these results may still underestimate the true effects that may occur in humans when mitochondrial Ca 2+ uptake is impaired. Our growing understanding of the pathophysiology of these processes in heart failure may aid the development of novel mitochondria-directed treatment options to ameliorate disease progression in these patients.
